Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MTPC, Anaphore Agree to Jointly Develop Drugs for Autoimmune Diseases
January 3, 2011
- Nippon Kayaku to Lead Antibody Biosimilar Market in Japan: Nomura Securities Report
January 3, 2011
- Eisai Applies for Marketing Authorization for Embolic Beads
January 3, 2011
- Sanofi-aventis to Tie Up with Merck Serono in Oncology
January 3, 2011
- Taiyo Holds Meetings with Clients on GMP Compliance Measures
January 3, 2011
- ARBs Effective for Improving Albuminuria: DSP survey
January 3, 2011
- DSP Completes Merger of Chinese Subsidiaries
January 3, 2011
- US Generics Market to Outgrow New Drugs Market: IGPA Annual Conference
January 3, 2011
- Pfizer Applies for Solu-Medrol Based on Data from the Public Domain
January 3, 2011
- Shionogi, Wakamoto to Copromote Non-prescription Oral Care Products
January 3, 2011
- Apollo Medical to Expand Overseas Training Program for Its Employees
January 3, 2011
- FDA Recommends Withdrawal of Approval for Breast Cancer for Avastin
January 3, 2011
- EPS Acquires SMO in Taiwan
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (1)
January 3, 2011
- Eisai, Elan Settle Zonegran Off-Label Promotion Disputes
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (2)
January 3, 2011
- M3 to Expand Its e-Detailing Services in Oncology
January 3, 2011
- Seikagaku to File NDA for SI-6603 in Mid 2011
January 3, 2011
- PSJ to Raise Public Awareness of Drugs
January 3, 2011
- Ono Obtains Positive PIIb Results for Carfilzomib
January 3, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…